Discontinued — last reported Q4 '23
Products & Services · Deferred revenues, noncurrent
Paxlovid — Deferred revenues, noncurrent
Analysis
StatementSegment
First reportedQ4 2023
Last reportedQ4 2023Feb 22, 2024
Rolls up toContract Liabilities
Metric ID:
pfe_segment_paxlovid_deferred_revenues_noncurrentHistorical Data
1 periods
| Q4 '23 | |
|---|---|
| Value | $1.9B |
Frequently Asked Questions
- What is Pfizer's paxlovid — deferred revenues, noncurrent?
- Pfizer (PFE) reported paxlovid — deferred revenues, noncurrent of $1.9B in Q4 2023.